Affiliation:
1. Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine,
Sichuan University, Chengdu, 610 041, China
2. Division of Liver Transplantation, Department of Surgery, West China
Hospital, Sichuan University, Chengdu, 610 041, China
Abstract
Introduction:
Hepatocellular carcinoma (HCC) has a high mortality rate, with curative
resection being the primary treatment. However, HCC patients have a large possibility of recurrence
within 5 years after curative resection.
Method:
Thus, identifying biomarkers to predict recurrence is crucial. In our study, we analyzed
data from CCLE, GEO, and TCGA, identifying eight oncogenes associated with HCC. Subsequently,
the expression of 8 genes was tested in 5 cases of tumor tissues and the adjacent non-tumor
tissues. Then ATP6AP1, PSMD14 and HSP90AB1 were selected to verify the expression in
63 cases of tumor tissues and the adjacent non-tumor tissues. The results showed that ATP6AP1,
PSMD14, HSP90AB1 were generally highly expressed in tumor tissues. A five-year follow-up of
the 63 clinical cases, combined with Kaplan-Meier Plotter's relapse-free survival (RFS) analysis,
found a significant correlation between PSMD14 expression and recurrence in HCC patients. Subsequently,
we analyzed the PSMD14 mutations and found that the PSMD14 gene mutations can
lead to a shorter disease-free survival time for HCC patients.
Results:
The results of enrichment analysis indicated that the differentially expressed genes related
to PSMD14 are mainly enriched in the signal release pathway.
Conclusion:
In conclusion, our research showed that PSMD14 might be related to recurrence in
HCC patients, and the expression of PSMD14 in tumor tissue might be a potential prognostic biomarker
after tumor resection in HCC patients.
Funder
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Genetics (clinical),Genetics